To obtain a new nontoxic tricyclic amide having selective and very high affinity for melatonin receptors, exhibiting high activity against the melatoninergic system among others, and useful in treating periodic depression, sleep disorders, cardiovascular diseases and the like.
This new compound is shown by formula I {A is such as to be joined together with the group binding it to form a group of formula H [R1 to R6 are each H, a halogen, hydroxy or the like; X1 S, O, C(R5)=C(R6) or the like]; dotted line denotes a single or double bond; Y is C(R9)(R10) (R9 and R10 are each H, an alkyl or the like); (n) is an integer of 1-3; R7 is H, an alkyl, aryl or the like; R8 is CO-R11 [R11 is the same as R12 (R12 is H, an alkyl, alkenyl, or the like)] or the like}, e.g. N-(2,3-dihydro-1H-phenalen-2-yl) acetamicie. The compound of formula I is obtained, for example, by cyclizing a compound of formula IV ((n') is, 0, 1 or 2).
MATHE ALLAINMAT MONIQUE (FR)
DELAGRANGE PHILIPPE (FR)
RENARD PIERRE (FR)
GUARDIOLA LEMAITRE BEATRICE (FR)